Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial Meeting Abstract
| Authors: | Nicolle, R.; Bachet, J. B.; Harlé, A.; Iovanna, J. L.; Hammel, P.; Rebours, V.; Turpin, A.; Ben Abdelghani, M.; Wei, A.; Mitry, E.; Lopez, A.; Biagi, J.; Francois, E.; Artru, P.; Lambert, A.; Renouf, D. J.; Mauduit, M.; Dussetti, N.; Conroy, T.; Cros, J. |
| Abstract Title: | Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-08-01 |
| Start Page: | S1136 |
| Language: | English |
| ACCESSION: | WOS:000866211601557 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2022.07.1429 |
| Notes: | Meeting Abstract: 1297P -- Source: Wos |
